Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Drugs for Rare Diseases (DRD) Sub-Report offers credible, relevant insights related to DRD files to support a company’s reimbursement forecasting needs.

WHY DO YOU NEED THIS SUB-REPORT?

The CRaFT DRD Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the DRD public market reimbursement process – from HTA submission to provincial funding.

WHAT DOES THE REPORT INCLUDE?

This CRaFT DRD Sub-Report includes 30+ page of insights on DRD drugs reviewed by CADTH from 2017-2021 related to:

  • CADTH review volume & timeline
  • pCPA volume for initiated, completed, closed, and not-negotiated files
  • pCPA under-consideration and under-negotiation timeline
  • Funding volume & timeline for each jurisdiction
  • Timeline Comparison: DRD and Other Types of Files
  • Market access timeline forecasting (from HTA submission to first funding)

For further information on the content and pricing of CRaFT and the Drugs for Rare Diseases (DRD) Sub-report, please complete your contact information on our main CRaFT Report page.

← Back to Main CRaFT Report
Canadian Reimbursement and Forecasting Timelines (CRaFT) - Drugs for Rare Diseases Sub-Report, June 2021 Update
Learn More
Learn More

You're viewing an older edition

The latest CRaFT 2026 report has updated reimbursement data, forecasts, and trends. Get the most current insights.

View the 2026 CRaFT Report → Go to homepage